JP7721142B2 - Ｍａｓｐ－２阻害剤および使用方法 - Google Patents
Ｍａｓｐ－２阻害剤および使用方法Info
- Publication number
- JP7721142B2 JP7721142B2 JP2022533447A JP2022533447A JP7721142B2 JP 7721142 B2 JP7721142 B2 JP 7721142B2 JP 2022533447 A JP2022533447 A JP 2022533447A JP 2022533447 A JP2022533447 A JP 2022533447A JP 7721142 B2 JP7721142 B2 JP 7721142B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- unsubstituted
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943629P | 2019-12-04 | 2019-12-04 | |
| US62/943,629 | 2019-12-04 | ||
| PCT/US2020/063391 WO2021113698A1 (en) | 2019-12-04 | 2020-12-04 | Masp-2 inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504541A JP2023504541A (ja) | 2023-02-03 |
| JP2023504541A5 JP2023504541A5 (https=) | 2023-10-05 |
| JP7721142B2 true JP7721142B2 (ja) | 2025-08-12 |
Family
ID=74106147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533447A Active JP7721142B2 (ja) | 2019-12-04 | 2020-12-04 | Ｍａｓｐ－２阻害剤および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US12030853B2 (https=) |
| EP (1) | EP4069676A1 (https=) |
| JP (1) | JP7721142B2 (https=) |
| AU (1) | AU2020395306B2 (https=) |
| CA (1) | CA3159159A1 (https=) |
| WO (1) | WO2021113698A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311042B1 (en) | 2018-05-29 | 2026-04-01 | Omeros Corp | MASP-2 inhibitors and methods of use |
| EP4069676A1 (en) * | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| IL293588B1 (en) | 2019-12-04 | 2026-04-01 | Omeros Corp | 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof |
| EP4069678A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| TWI834025B (zh) | 2020-03-06 | 2024-03-01 | 美商奥默羅斯公司 | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010515729A (ja) | 2007-01-10 | 2010-05-13 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
| JP2014506877A (ja) | 2011-01-04 | 2014-03-20 | ノバルティス アーゲー | 加齢性黄斑変性症（ａｍｄ）の処置に有用なインドール化合物またはそのアナログ |
| JP2017508789A (ja) | 2014-02-25 | 2017-03-30 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体媒介障害の治療のための化合物 |
| WO2019186164A1 (en) | 2018-03-29 | 2019-10-03 | University Of Leeds | Factor xiia inhibitors |
| WO2019211585A1 (en) | 2018-04-30 | 2019-11-07 | University Of Leeds | FACTOR XIIa INHIBITORS |
| JP2022552048A (ja) | 2019-08-21 | 2022-12-15 | カルビスタ・ファーマシューティカルズ・リミテッド | 酵素阻害剤 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| MC2115A1 (fr) | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| IL112795A (en) | 1994-03-04 | 2001-01-28 | Astrazeneca Ab | Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US5866573A (en) | 1997-04-21 | 1999-02-02 | Merck & Co., Inc. | Pyrazinone thrombin inhibitors |
| AU742178B2 (en) | 1998-05-26 | 2001-12-20 | Merck & Co., Inc. | Imidazopyridine thrombin inhibitors |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| AU3192500A (en) | 1999-03-16 | 2000-10-04 | C & C Research Laboratories | Substituted proline derivatives and medicinal compositions containing the same |
| US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
| US6664255B1 (en) | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| CZ20014115A3 (cs) | 1999-05-19 | 2002-05-15 | Pharmacia Corporation | Substituované polycyklické aryl a heteroaryl pyrazinony vhodné pro selektivní inhibici koagulační kaskády |
| US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| US20040072862A1 (en) | 1999-06-04 | 2004-04-15 | Bitler Catherine M. | Compositions for treating ischemia-related neuronal damage |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| WO2001079195A2 (en) | 2000-04-14 | 2001-10-25 | Corvas International, Inc. | Pyridine and pyrazine derivatives as thrombin inhibitors |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| AU2002230836A1 (en) | 2000-12-18 | 2002-07-01 | Merck & Co., Inc. | Benzylamine derivatives and their use as thrombin inhibitors |
| MXPA04003167A (es) | 2001-10-03 | 2004-07-08 | Pharmacia Corp | Compuestos heterociclicos insaturados de 6 miembros utiles para la inhibicion selectiva de la cascada de coagulacion. |
| JP2005509606A (ja) | 2001-10-03 | 2005-04-14 | ファルマシア・コーポレーション | 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ |
| ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
| WO2004032834A2 (en) | 2002-10-04 | 2004-04-22 | Merck & Co., Inc. | Thrombin inhibitors |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| US20140056873A1 (en) | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| ES2631127T3 (es) | 2004-06-10 | 2017-08-28 | Omeros Corporation | Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR20080002832A (ko) * | 2005-03-16 | 2008-01-04 | 얀센 파마슈티카 엔.브이. | 보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민 |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| DK2488203T3 (en) | 2009-10-16 | 2017-03-13 | Omeros Corp | METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| HUP1000366A2 (en) | 2010-07-13 | 2012-03-28 | Mta Enzimologiai Intezet | Novel proteins, their production process and use tereof |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| BR112013025917A2 (pt) | 2011-04-08 | 2016-12-20 | Omeros Corp | uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2 |
| HUE049154T2 (hu) | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
| AU2013201779B2 (en) | 2011-05-04 | 2016-01-07 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement activation |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| MX357540B (es) | 2012-04-06 | 2018-07-13 | Omeros Corp | Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna. |
| BR112014031522A2 (pt) | 2012-06-18 | 2017-08-01 | Omeros Corp | métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento |
| AR091490A1 (es) | 2012-06-19 | 2015-02-11 | Bristol Myers Squibb Co | Antagonistas de iap |
| EP2906236A1 (en) | 2012-10-10 | 2015-08-19 | Novo Nordisk Health Care AG | Liquid pharmaceutical composition of factor vii polypeptide |
| EP2922535B1 (en) | 2012-11-20 | 2021-11-10 | Merck Sharp & Dohme Corp. | Thrombin inhibitors |
| JP2016539919A (ja) | 2013-10-17 | 2016-12-22 | オメロス コーポレーション | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| CA2935683A1 (en) | 2013-12-30 | 2015-07-09 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| AU2016354117B2 (en) | 2015-11-09 | 2019-11-28 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR102528260B1 (ko) | 2016-01-05 | 2023-05-04 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
| US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| MX2018011648A (es) | 2016-03-31 | 2019-01-30 | Omeros Corp | Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo. |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| US20180105604A1 (en) | 2016-10-13 | 2018-04-19 | University Of Leicester | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
| TWI881481B (zh) | 2017-08-15 | 2025-04-21 | 美商歐米諾斯公司 | 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法 |
| PE20200924A1 (es) | 2017-09-13 | 2020-09-14 | Amgen Inc | Compuestos de bisamida sustituida que activan el sarcomero cardiaco |
| IL311042B1 (en) | 2018-05-29 | 2026-04-01 | Omeros Corp | MASP-2 inhibitors and methods of use |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| EP4069676A1 (en) * | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| EP4069678A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| IL293588B1 (en) | 2019-12-04 | 2026-04-01 | Omeros Corp | 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
-
2020
- 2020-12-04 EP EP20834036.4A patent/EP4069676A1/en active Pending
- 2020-12-04 AU AU2020395306A patent/AU2020395306B2/en active Active
- 2020-12-04 CA CA3159159A patent/CA3159159A1/en active Pending
- 2020-12-04 WO PCT/US2020/063391 patent/WO2021113698A1/en not_active Ceased
- 2020-12-04 US US17/112,873 patent/US12030853B2/en active Active
- 2020-12-04 JP JP2022533447A patent/JP7721142B2/ja active Active
-
2024
- 2024-05-31 US US18/680,563 patent/US20240317682A1/en active Pending
- 2024-05-31 US US18/679,774 patent/US20240351980A1/en active Pending
-
2025
- 2025-03-05 US US19/071,565 patent/US20250197349A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010515729A (ja) | 2007-01-10 | 2010-05-13 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
| JP2014506877A (ja) | 2011-01-04 | 2014-03-20 | ノバルティス アーゲー | 加齢性黄斑変性症（ａｍｄ）の処置に有用なインドール化合物またはそのアナログ |
| JP2017508789A (ja) | 2014-02-25 | 2017-03-30 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体媒介障害の治療のための化合物 |
| WO2019186164A1 (en) | 2018-03-29 | 2019-10-03 | University Of Leeds | Factor xiia inhibitors |
| WO2019211585A1 (en) | 2018-04-30 | 2019-11-07 | University Of Leeds | FACTOR XIIa INHIBITORS |
| JP2022552048A (ja) | 2019-08-21 | 2022-12-15 | カルビスタ・ファーマシューティカルズ・リミテッド | 酵素阻害剤 |
Non-Patent Citations (1)
| Title |
|---|
| REGISTRY(STN)[online]，2011.12.05-2004.09.21, [検索日] 2024.07.31 CAS登録番号 749177-11-5, 1348395-03-8, 1348431-17-3, 1348728-96-0, 1348730-54-0 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4069676A1 (en) | 2022-10-12 |
| AU2020395306B2 (en) | 2025-04-24 |
| US20240317682A1 (en) | 2024-09-26 |
| US12030853B2 (en) | 2024-07-09 |
| US20210171461A1 (en) | 2021-06-10 |
| JP2023504541A (ja) | 2023-02-03 |
| US20250197349A1 (en) | 2025-06-19 |
| CA3159159A1 (en) | 2021-06-10 |
| AU2020395306A1 (en) | 2022-06-30 |
| WO2021113698A1 (en) | 2021-06-10 |
| US20240351980A1 (en) | 2024-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| US12486278B2 (en) | MASP-2 inhibitors and methods of use | |
| JP7721143B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| JP7699389B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| AU2023266363A1 (en) | MASP-2 inhibitors and methods of use | |
| US20240228499A1 (en) | Masp-2 inhibitors and methods of use | |
| TW202523310A (zh) | Ｍａｓｐ－２抑制劑及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230927 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230927 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240215 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240822 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250327 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250707 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250723 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7721142 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |